{"filings":[{"id":2079244,"accession_number":"0001628280-26-053378","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-08-05T20:16:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics updates corporate presentation for investor meetings; no specific new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an 8-K on August 5, 2026, to furnish an updated corporate presentation as Exhibit 99.1.","Presentation titled 'Advancing T Cell Engagers for Solid Tumors' but full content not provided in filing.","No financial results, clinical data, or material events announced in the 8-K body.","Routine FD disclosure; presentation used for meetings with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1995159,"accession_number":"0001628280-26-051399","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-07-31T20:08:44+00:00","items":["3.01"],"status":"ready","headline":"Context Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Context on July 29, 2026 of non-compliance with Minimum Bid Price Rule (bid below $1.00 for 30 consecutive business days).","Company has 180 calendar days, until January 25, 2027, to regain compliance by closing at $1.00 or more for 10 consecutive business days.","If not compliant by Jan 25, 2027, may be eligible for a second 180-day period if it meets other listing standards and notifies Nasdaq of intent to cure.","Company intends to monitor bid price and evaluate options, but no assurance of regaining compliance or avoiding delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1303997,"accession_number":"0001628280-26-045744","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-06-26T20:07:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Context Therapeutics stockholders approve increase in authorized common shares to 300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 200M to 300M via Certificate of Amendment filed June 24, 2026.","All seven director nominees elected with >63M votes for each; no dissident candidates.","Ratification of CohnReznick LLP as independent auditor for FY2026 approved with 72.76M votes.","91.88M shares outstanding; 79.27% quorum at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1040236,"accession_number":"0001628280-26-043042","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-06-15T13:18:44+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics reports 29% ORR for CTIM-76 in Phase 1 PROC trial; FDA Fast Track granted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["29% confirmed overall response rate per RECIST v1.1 in heavily pretreated PROC patients (median 7 prior lines).","Cytokine Release Syndrome limited to Grade 1 in 11% of PROC patients at active doses; supports outpatient dosing.","PK data supports exploration of Q3W dosing in 2H 2026; Phase 1b dose expansion planned for 2027.","CTIM-76 granted FDA Fast Track Designation for platinum-resistant ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":481836,"accession_number":"0001628280-26-035793","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-05-18T10:47:00+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Context Therapeutics buys out future milestones and royalties for CT-202 from BioAtla for $6.5M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.","License becomes irrevocable, royalty-free, fully paid-up, and non-terminable.","BioAtla no longer entitled to future milestones or royalties for CT-202.","Phase 1 trial initiation for CT-202 expected in Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96135,"accession_number":"0001628280-26-029323","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics resolves stockholder class action; $850K mootness fee paid by third party","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Delaware court invalidated classified board and for-cause removal provisions from charter.","Third-party service provider agreed to pay $850,000 mootness fee; company did not pay.","Fee paid May 1, 2026; action to close after annual meeting scheduled June 24, 2026.","Stipulated order granted April 30, 2026; court retains jurisdiction only for mootness fee application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96134,"accession_number":"0001628280-26-022931","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.","Phase 1a trial evaluating CTIM-76 in CLDN6-positive ovarian, endometrial, and testicular cancers is ongoing.","Interim data from the Phase 1a trial expected in June 2026.","Fast Track aims to expedite development and review for serious conditions with unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109768,"accession_number":"0001628280-26-020517","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics releases updated corporate presentation focused on T cell engagers for solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation updated March 23, 2026 for investor and analyst meetings.","Slides emphasize advancing T cell engager platform for solid tumors; no financial or clinical data disclosed.","Slides 15 and 32 incorporated into Item 8.01, but specific content not detailed in filing.","Previous presentation replaced; no new pipeline milestones, partnerships, or financing announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109767,"accession_number":"0001628280-26-017691","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Context Therapeutics removes classified board and for-cause removal after court-approved settlement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court approved stipulation invalidating 3-year director terms and for-cause removal provisions from charter.","Certificate of Correction filed with Delaware Secretary of State on March 11, 2026.","Directors' terms expire at 2026 annual meeting; directors can be removed with or without cause by majority vote.","Stockholder class action dismissed with prejudice as to plaintiff; court retains jurisdiction over mootness fee.","2026 annual meeting set for June 24, 2026; record date April 27, 2026; nominees will serve one-year terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109766,"accession_number":"0001628280-26-012813","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics settles governance lawsuit; annual director elections June 24, 2026","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Stipulated consent judgment filed Feb 24 invalidates three-year director terms and for-cause removal from charter.","Class action by Vladimir Gusinsky Revocable Trust will be dismissed with prejudice; charter corrected if court approves.","Annual meeting set for June 24, 2026; record date April 27, 2026; agenda includes election of directors to one-year terms.","Stockholder proposals and director nominations due by March 14, 2026; universal proxy notices due by April 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109765,"accession_number":"0001628280-26-001275","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics files updated corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing updates corporate presentation for investor meetings; presentation content not included in this 8-K.","No financial results, pipeline updates, or guidance changes announced.","Event is a routine FD disclosure; no material impact expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126299,"accession_number":"0001628280-25-049604","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.","CTIM-76 Phase 1: 12 patients; RECIST response observed from Cohort 3; no CRS>Grade1, no DLT.","CT-95 Phase 1: 6 patients; approaching target dose with Cohort 4; no CRS>Grade2.","CT-202 (Nectin-4 x CD3) preclinical; expects regulatory filing for first-in-human trial in Q2 2026.","Anticipates updated CTIM-76 Phase 1a data and Phase 1b dose selection in Q2 2026; CT-95 data mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126298,"accession_number":"0001628280-25-046258","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics amends ATM agreement to increase offering capacity to up to $75M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prior ATM: sold 14.7M shares for ~$15M through Dec 2, 2024 to Oct 24, 2025.","Amendment raises aggregate offering to $75M (excl. prior sales) under new S-3 effective Nov 14, 2024.","New prospectus supplement dated Oct 24, 2025; agent Leerink commission up to 3% of gross proceeds.","Proceeds intended for R&D, working capital, and general corporate purposes.","Prior ATM prospectus terminated; no further sales under that facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126297,"accession_number":"0001628280-25-045513","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Oct 17, 2025 confirming compliance regained after 10 consecutive business days with closing bid price at or above $1.00.","Company had been noncompliant since Feb 27, 2025; granted extension to Feb 23, 2026.","Nasdaq considers the matter closed; delisting risk removed.","Stock ticker CNTX trades on Nasdaq under Minimum Bid Price Rule 5550(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143048,"accession_number":"0001842952-25-000085","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Context Therapeutics receives Nasdaq extension until Feb 23, 2026 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq extension letter on Aug 28, 2025; new compliance deadline Feb 23, 2026.","Originally notified of non-compliance on Feb 27, 2025; need $1.00 closing bid for 30 consecutive days.","Company may consider reverse stock split to regain bid price compliance.","Listing and trading of CNTX common stock unaffected by extension letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161160,"accession_number":"0001842952-25-000072","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Context Therapeutics stockholders approve reverse stock split and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["66,716,026 shares (74.37% of outstanding) present at June 12, 2025 annual meeting.","Ratified CohnReznick LLP as auditor for FY2025 with 66,649,293 votes for, 20,039 against.","Approved reverse stock split at ratio from 1:5 to 1:50, as determined by Board; 65,141,783 for, 1,540,542 against.","No broker non-votes reported; both proposals were routine matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161159,"accession_number":"0001842952-25-000051","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics updates corporate presentation for June 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company issued an updated corporate presentation dated June 2025.","Presentation emphasizes T cell engager platform for solid tumors.","Slide 17 of the presentation is incorporated by reference under Item 8.01.","No clinical data, financial results, or guidance were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161158,"accession_number":"0001842952-25-000037","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics doses first patient in Phase 1 trial of CT-95 bispecific antibody","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody targeting MSLN-expressing cancers.","Second TCE bispecific to enter clinic in 2025 following CTIM-76 (Claudin 6 x CD3) earlier this year.","Phase 1 open-label dose escalation and expansion study for advanced solid tumors (ovarian, pancreatic, lung, mesothelioma).","Initial data for CT-95 Phase 1 trial expected in mid-2026.","CEO Martin Lehr highlights expansion of clinical pipeline and leadership in TCE therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179323,"accession_number":"0001842952-25-000024","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Context Therapeutics receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Feb 27, 2025 for failing $1.00 minimum bid price for 30 consecutive business days.","Initial 180-day cure period runs until August 26, 2025 to regain compliance.","Must have closing bid price of $1.00+ for at least 10 consecutive business days to cure.","Company will monitor and evaluate options, but no assurance of regaining compliance.","If not cured by Aug 26, may be eligible for an additional 180-day grace period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179322,"accession_number":"0001842952-25-000006","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).","Trial targets CLDN6-positive advanced/metastatic ovarian, endometrial, and testicular cancers.","Study expected to enroll up to 70 patients; initial data anticipated first half of 2026.","CEO Martin Lehr highlights the milestone as key pipeline advancement.","Company presented at SITC 2024 supporting first-in-human dose selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179321,"accession_number":"0001842952-25-000003","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Context Therapeutics appoints Andy Pasternak as Chairman; Richard Berman resigns from Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Berman resigned from Board effective Jan 12, 2025; not due to any disagreement with the Company.","Andy Pasternak appointed Chairman effective Jan 13, 2025; term through 2027 annual meeting.","Pasternak also appointed to Audit and Compensation Committees; Dr. Karen L. Smith named Compensation Committee Chair.","Pasternak granted options to purchase 20,685 shares, vesting by June 13, 2025 or 2025 annual meeting; receives $55K annual cash retainer.","Pasternak brings 25+ years pharma experience, including role in $28B Horizon-Amgen acquisition and Bain Healthcare leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195998,"accession_number":"0001842952-24-000087","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics sells 14.7M shares for ~$15M to MPM BioImpact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 14,705,882 shares at ~$1.02/share for aggregate gross proceeds of ~$15M.","Shares purchased by MPM BioImpact LLC under sales agreement with Leerink Partners dated Dec 2, 2024.","Proceeds expected to fund working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195997,"accession_number":"0001628280-24-049570","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics enters $75M at-the-market equity offering with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility allows sale of up to $75M of common stock from time to time.","Leerink Partners receives 3.0% commission on gross proceeds; company reimburses certain expenses.","Net proceeds to fund R&D of product candidates and working capital / general corporate purposes.","Shares offered under effective S-3 filed Nov 2022; prospectus supplement dated Dec 2, 2024.","Company not obligated to sell any shares; agreement terminates upon full sale or earlier termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212266,"accession_number":"0001842952-24-000083","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.","CT-202 (formerly BA3362) IND filing expected mid-2026; Context to fund all development.","Cash runway into 2027 covering CTIM-76 and CT-95 Phase 1 trials plus CT-202 IND expenses.","First CTIM-76 patient dosing expected Oct/Nov 2024; initial dose escalation data 1H 2026.","CT-95 Phase 1 initial dose escalation data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212265,"accession_number":"0001842952-24-000081","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Context Therapeutics stockholders approve doubling authorized shares to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 42,389,461 for, 790,853 against, 71,655 abstain to increase authorized common shares to 200,000,000.","Authorization increased from 100,000,000 to 200,000,000 shares of common stock.","Special Meeting held September 17, 2024; quorum of 43,251,969 shares (57.67%) present.","Proposal also included approval of adjournments if needed, passed with 42,447,035 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212264,"accession_number":"0001842952-24-000070","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Context Therapeutics appoints Dr. Karen Smith and Dr. Luke Walker to Board; board expands to 7 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 5 to 7; Dr. Smith (former CMO of Jazz Pharmaceuticals) and Dr. Walker (former CMO of Harpoon Therapeutics) join.","Dr. Smith assigned to Compensation Committee; Dr. Walker to Nominating Committee; both deemed independent under Nasdaq rules.","Each new director received option to purchase 19,315 shares, vesting on earlier of June 13, 2025 or 2025 annual meeting.","Dr. Smith brings over 20 years of oncology drug development (Herceptin, Vyxeos) and regulatory experience; Dr. Walker led Tukysa (tucatinib) development at Seagen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212263,"accession_number":"0001842952-24-000050","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.","CT-95 is IND-cleared; Phase 1 trial expected to initiate in Q1 2025.","Targets mesothelin, prevalent in ovarian, lung, and pancreatic cancers.","Advancement through Phase 1 dose escalation to be funded with existing cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231186,"accession_number":"0001842952-24-000041","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Context Therapeutics Stockholders Ratify Auditor and Elect Directors at Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratified CohnReznick LLP as auditor for 2024 with 8,364,879 votes for, 117,835 against.","Elected directors Richard Berman, Dr. Philip Kantoff, Martin Lehr, Jennifer Evans Stacey, Linda West to board.","Director Martin Lehr received highest votes for (6,637,406), Richard Berman lowest (4,774,152).","Proxies represented 53.15% of outstanding shares (8,486,458 votes) out of 15,966,053 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231185,"accession_number":"0001842952-24-000033","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics raises ~$100M via private placement; FDA clears IND for CTIM-76","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement raises ~$100M gross via 64.5M shares/pre-funded warrants at $1.55/share.","FDA cleared IND for CTIM-76 (CLDN6 x CD3 bispecific) for Phase 1 in CLDN6-positive gynecologic/testicular cancers.","First patient enrollment for dose escalation expected mid-2024; Phase 1 study to enroll up to 70 patients.","Proceeds plus existing cash extend cash runway into 2028, covering estimated Phase 1 trial duration.","Private placement led by Nextech, with participation from Ally Bridge, Avidity, Blackstone, Blue Owl, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231184,"accession_number":"0001842952-24-000022","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.","Phase 1 dose escalation/expansion trial planned in CLDN6-positive gynecologic and testicular cancers.","CEO Martin Lehr calls IND submission a significant milestone for the company.","Company set aggressive 2021 timeline and prioritized CTIM-76 as potentially best-in-class therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249570,"accession_number":"0001842952-24-000010","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Context Therapeutics amends bylaws to reduce quorum to one-third, update proxy rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum reduced to one-third of outstanding shares entitled to vote, effective immediately.","Stockholder list at meetings no longer required; notice rules for director nominations updated.","Proxies soliciting under Rule 14a-19 must certify compliance and provide evidence 5 days before meeting.","Non-compliant nominations deemed void; white proxy cards reserved for Board of Directors only.","Technical, clarifying and conforming changes also adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249569,"accession_number":"0001842952-24-000005","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Context Therapeutics amends Integral license for CTIM-76 after finding potential third-party patent conflict","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.","Amendment reduces development milestones from $55M to $15M, sales milestones from $130M to $12.5M.","Royalty reduced from 8–12% to flat 6% on net sales, starting no sooner than February 2034.","License narrowed to only CTIM-76; company no longer obligated to reimburse Integral for research funding.","Deal includes mutual releases and revised milestone triggers tied to Phase 1b/2, Phase 3, and marketing approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267028,"accession_number":"0001842952-23-000082","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics reports preclinical CTIM-76 data showing tumor regressions; IND on track for Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTIM-76 induced dose-proportional tumor regressions and was well tolerated in xenograft models.","CTIM-76 showed ten-fold higher potency than AMG-794 in in vitro cytotoxicity and cytokine activation assays.","CTIM-76 retained activity across low to high CLDN6 expression, unlike TORL-1-23 which depended on high expression.","IND filing for CTIM-76 planned for late Q1 2024.","Approximately 70,000 US patients with CLDN6-positive metastatic solid tumors have no approved targeted treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284306,"accession_number":"0001842952-23-000074","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics updates corporate presentation for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On August 7, 2023, Context Therapeutics updated its corporate presentation for use in investor meetings.","The presentation was filed as Exhibit 99.1 to Form 8-K.","The company's CEO Martin A. Lehr signed the filing.","The presentation includes information about advancing medicines for solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303958,"accession_number":"0001842952-23-000070","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Non-compliance with Minimum Bid Price Rule first disclosed on Jan 24, 2023; initial cure period ran to July 24, 2023.","On June 15, 2023, Nasdaq confirmed the company's common stock had a closing bid price of $1.00+ for 10 consecutive business days.","Nasdaq considers the matter closed; the company has regained compliance with Listing Rule 5550(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303957,"accession_number":"0001842952-23-000065","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Context Therapeutics 2023 annual meeting: auditor ratified, reverse stock split not approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratification of CohnReznick LLP as independent auditor for FY2023 approved with 9,827,096 for, 232,432 against, 109,961 abstentions.","Proposal to amend charter for reverse stock split (1:2 to 1:50) failed: 7,809,550 for, 2,326,090 against, 33,849 abstentions, not reaching majority of outstanding shares.","Quorum of 63.69% (10,169,489 shares) present at May 31, 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323671,"accession_number":"0001842952-23-000040","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","2.05","7.01","9.01"],"status":"ready","headline":"Context Therapeutics discontinues ONA-XR, prioritizes CTIM-76; 2022 net loss $14.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued ONA-XR due to elevated LFTs in 3 patients and competitive landscape; exploring strategic options.","Focusing on CTIM-76 (CLDN6 x CD3 bispecific) for solid tumors; IND expected Q1 2024.","Cash $35.5M at Dec 31, 2022, down from $49.7M; cash runway extended into late 2024.","2022 net loss $14.8M vs $10.5M in 2021; R&D $7.1M, G&A $7.8M.","CTIM-76 preclinical data at AACR April 17, 2023; investor R&D webinar same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323670,"accession_number":"0001842952-23-000015","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics reports positive Phase 2 OATH data for ONA-XR in endometrial cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two confirmed partial responses among first 12 patients (9 evaluable) in Phase 2 trial of ONA-XR plus anastrozole for HR+ metastatic endometrial cancer.","4-month progression-free survival rate of 77% and overall response rate of 22%; no drug-related discontinuations observed.","Compared to historical KEYNOTE-775 trial: ONA-XR+ANA showed higher 4-month PFS (77% vs 42% chemo, 67% Lenvima+Keytruda) and lower discontinuation (0% vs 8% and 33%).","Drug well-tolerated with mainly Grade 1-2 adverse events; updated data expected in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323669,"accession_number":"0001842952-23-000010","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Context Therapeutics receives Nasdaq notice for non-compliance with minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Jan 24, 2023, for bid price below $1.00 for 30 consecutive business days.","No immediate effect on listing or trading; 180-day compliance period ends July 24, 2023.","Can regain compliance if bid price closes at $1.00+ for 10 consecutive business days before deadline.","Company monitoring bid price and evaluating options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323668,"accession_number":"0001842952-23-000004","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics highlights 2023 priorities: CTIM-76 candidate, ONA-XR data updates, cash runway into Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody candidate; IND filing expected Q1 2024.","ONA-XR Phase 2 endometrial cancer (OATH) shows 77% 4-month PFS rate; additional data expected mid-2023.","ONA-XR Phase 2 breast cancer (SMILE) shows 44% 4-month PFS rate; additional data expected Q4 2023.","ELONA Phase 1b/2 breast cancer trial with Menarini's elacestrant opened and enrolled first patient.","Cash and equivalents $39.4M as of Sep 30, 2022; expected to fund operations into Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341677,"accession_number":"0001842952-22-000108","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context reports preliminary Phase 2 data for ONA-XR: 4-month PFS rate of 44% in metastatic breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4-month progression-free survival (PFS) rate of 44% in ER+, HER2- metastatic breast cancer patients in SMILE trial.","ONA-XR combined with fulvestrant showed favorable safety and tolerability in second- or third-line setting.","Previously disclosed endometrial cancer data showed 4-month PFS rate of 77% with anastrozole combination.","ELONA Phase 1b/2 trial combining ONA-XR with elacestrant; Phase 1b data expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341676,"accession_number":"0001842952-22-000104","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics nominates CTIM-76 as lead CLDN6 bispecific; IND expected Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTIM-76 is a CLDN6 x CD3 bispecific antibody with silenced Fc to reduce aberrant T-cell activation.","IND submission for CTIM-76 planned for Q1 2024 to the FDA.","Targets CLDN6-positive solid tumors including ovarian, endometrial, testicular, and gastric cancers.","Preclinical data show potent lysis of CLDN6+ cancer cells with minimal free cytokine release.","Collaboration with Integral Molecular; webinar on December 1, 2022, at 11 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341675,"accession_number":"0001842952-22-000098","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics updates corporate deck; no new material financial or clinical details.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation updated as of November 2022 for investor meetings.","No specific financial results, clinical data, or strategic milestones announced.","Presentation reiterates focus on advancing medicines for female cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358594,"accession_number":"0001842952-22-000086","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-09-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics extends cash runway to Q1 2024, prioritizes key pipeline programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash runway extended to Q1 2024; deferring noncritical R&D and reducing overhead.","ONA-XR ELONA Phase 1b/2 trial with elacestrant for ER+/PR+/HER2- mBCa starts Q4 2022; data Q4 2023.","CLDN6xCD3 BsMAb candidate nomination Q4 2022; IND submission planned Q1 2024.","Preliminary data from ISTs: granulosa cell/endometrial cancer Nov 2022; breast cancer Dec 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358593,"accession_number":"0001842952-22-000066","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Context Therapeutics and Menarini collaborate for Phase 1b/2 trial of ONA-XR + elacestrant in ER+/PR+ HER2- mBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b/2 ELONA trial evaluating ONA-XR plus elacestrant expected to start Q4 2022.","Menarini supplies elacestrant at no cost; Context sponsors and funds the study.","Elacestrant Phase 3 showed 30% reduction in risk of progression or death vs SOC in ER+/HER2- mBC.","12-month PFS rate: 22% for elacestrant vs 9% for SOC in overall population.","Preclinical data suggest dual ER and PR blockade may enhance tumor control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377348,"accession_number":"0001842952-22-000050","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Context Therapeutics shareholders ratify CohnReznick as auditor for FY 2022","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held June 2, 2022; quorum of 9,161,941 shares (57.38%) present.","Proposal 1: Ratification of CohnReznick LLP as independent auditor for 2022.","Votes: 9,144,524 For, 8,877 Against, 8,540 Abstentions; no broker non-votes.","Auditor appointment for year ending December 31, 2022 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395729,"accession_number":"0001842952-22-000028","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Context Therapeutics reports FY2021 net loss of $10.5M; cash $49.7M into 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and restricted cash $49.7M at Dec 31, 2021 (vs $0.3M in 2020); expected to fund operations into 2024.","Net loss of $10.5M for FY2021 vs net income of $6.6M in 2020; R&D expenses $3.8M, G&A $3.6M.","Closed $31.25M private placement in Dec 2021; $28.75M IPO earlier; pipeline includes three Phase 2 ONA-XR trials and CLDN6 bsAb candidate selection in 2022.","Appointed Christopher Beck as SVP Operations and Mark Fletcher as VP R&D in Jan 2022.","Preliminary data expected mid-2022 from first-line metastatic breast cancer and recurrent endometrial cancer trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395728,"accession_number":"0001842952-22-000009","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Context Therapeutics updates corporate presentation, no new figures disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an updated corporate presentation dated January 2022 under Item 8.01.","Presentation titled 'Bringing Change for Female Cancers' but contains no disclosed financial or pipeline specifics.","No material operational or financial updates beyond the filing itself.","Ticker: CNTX; stock trades on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395727,"accession_number":"0001842952-22-000004","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Context Therapeutics announces leadership changes: Rencher retires, Beck and Fletcher appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bill Rencher, Ph.D., retired as Head of CMC effective Jan 1, 2022; transitions to advisory role at $8,000/month through Apr 2022.","Christopher Beck appointed SVP, Operations; previously VP of Program Management at Galera Therapeutics.","Mark Fletcher, Ph.D., appointed VP, R&D; previously VP of Product Development at Pharmaceutical Associates, Inc.","Appointments aim to advance lead candidate onapristone extended release (ONA-XR) in breast, ovarian, and endometrial cancers.","Rencher's retirement was planned, not due to disagreement; advisory role continues through October 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414529,"accession_number":"0001842952-21-000018","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2021-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Context Therapeutics closes $31.25M private placement of 5M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$31.25M from sale of 5M shares of common stock and 5M warrants at $6.25 per unit.","Warrants have 5.5-year term and exercise price of $6.25 per share.","ThinkEquity acted as sole placement agent for the offering.","Company to file resale registration statement with SEC for shares and warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-06T23:59:59+00:00|414529"}